Paper Details

  1. Home
  2. Paper Details

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.

Author: , ArnoldDouglas L, CadavidDiego, CampbellNolan, ChangIh, DeykinAaron, ForrestalFiona, FreedmanMark S, GoldmanMyla D, HartungHans-Peter, HavrdováEva Kubala, HoPei-Ran, JefferyDouglas, KapoorRaju, LucasNisha, MikolDan, MillerAaron, SellebjergFinn, SteinerDeborah, YuBei

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

While treatments exist for multiple sclerosis (MS) that involves relapses, they have had less success for those with progressive MS. This study aims to determine whether a specific medication, natalizumab, can slow the progression of secondary progressive MS, even in patients who are not having relapses.
Paper Details　
Original Abstract of the Article :
Although several disease-modifying treatments are available for relapsing multiple sclerosis, treatment effects have been more modest in progressive multiple sclerosis and have been observed particularly in actively relapsing subgroups or those with lesion activity on imaging. We sought to assess wh...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1474-4422(18)30069-3

データ提供：米国国立医学図書館（NLM）

Natalizumab: A Potential Treatment for Secondary Progressive Multiple Sclerosis

Multiple sclerosis (MS) is a chronic neurological disease with a wide range of clinical presentations and treatment challenges. This study investigates the effectiveness of natalizumab, a monoclonal antibody, in slowing disease progression in secondary progressive MS (SPMS), a form of MS characterized by gradual neurological deterioration. The researchers conducted a phase 3, randomized, double-blind, placebo-controlled trial with an open-label extension to assess the impact of natalizumab on SPMS.

Natalizumab: A Promising Agent for SPMS

The study findings provide promising results for natalizumab as a potential treatment for SPMS. While natalizumab has shown effectiveness in relapsing MS, this study focuses on its impact on disease progression, independent of relapses. The study suggests that natalizumab may offer a benefit in slowing disease progression in SPMS, although further research is needed to confirm this finding.

Navigating the Shifting Sands of MS Treatment

Managing MS can be a challenging journey, like navigating a desert with shifting sands. This research provides valuable insights into the potential role of natalizumab in slowing disease progression in SPMS, offering hope for individuals facing this challenging condition.

Dr.Camel's Conclusion

This study provides valuable insights into the potential therapeutic benefits of natalizumab for SPMS. The researchers demonstrate a promising effect on disease progression, suggesting a potential role for natalizumab in managing this form of MS. Their work provides a glimmer of hope in the vast desert of MS research, offering a potential treatment option for individuals struggling with this complex and challenging condition.

Date :
  1. Date Completed 2019-03-15
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

29545067

DOI: Digital Object Identifier

10.1016/S1474-4422(18)30069-3

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.